Selecta Biosciences, Inc.
(NASDAQ : SELB)

( )
SELB After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.95%171.301.3%$495.18m
BIIBBiogen Inc.
0.91%235.041.3%$480.36m
CELGCelgene Corporation
0.11%96.361.3%$457.23m
GILDGilead Sciences, Inc.
-0.03%66.500.9%$434.72m
ILMNIllumina, Inc.
2.08%312.833.5%$317.70m
REGNRegeneron Pharmaceuticals, Inc.
3.27%320.092.6%$298.61m
AAgilent Technologies, Inc.
-0.50%67.981.6%$207.68m
VRTXVertex Pharmaceuticals Incorporated
1.92%172.371.9%$181.17m
EXASExact Sciences Corporation
-2.10%94.9125.3%$163.66m
ALXNAlexion Pharmaceuticals, Inc.
-0.97%127.552.0%$149.64m
BMRNBioMarin Pharmaceutical Inc.
0.25%87.694.3%$118.55m
SRPTSarepta Therapeutics, Inc.
0.36%121.6214.7%$112.14m
INCYIncyte Corporation
0.43%79.022.5%$105.72m
IONSIonis Pharmaceuticals, Inc.
-0.98%68.568.2%$98.74m
ALNYAlnylam Pharmaceuticals, Inc
-0.09%67.819.2%$94.94m

Company Profile

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.